Last updated: 2026-09-09 11:35:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Humacyte, Inc. (HUMA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.59, with a market capitalisation of $168.04M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.53 to $2.55. This page covers its latest market performance, valuation, price trends and company information.
$168.04M | |
$0.60 | |
$17.45 | |
$0.53 | |
$0.59 | |
5.98K | |
10.93M | |
-- | |
$2.55 | |
$0.53 | |
-- | |
-- |
Humacyte, Inc. (HUMA) is trading at $0.59 in pre-market trading as of 2026-09-09 11:15:00, down 0.32% ($0.00) from the previous close of $0.59
Pre-market trading shows how investors are pricing HUMA before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Humacyte, Inc. (HUMA) moved from $0.65 to $0.59, representing a decline of 8.78% ($0.06).
The stock traded between $0.57 and $0.70 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6.94 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.3%
HUMA is currently trading at $0.59, placing it 3.3% of the way from its 52-week low of $0.53 to its 52-week high of $2.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 184 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Humacyte, Inc. (HUMA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.